NEW YORK (GenomeWeb) – Due to the availability of new data, Medicare contractor Noridian said it will retire a recently issued draft local coverage determination in which it proposed to limit coverage for a number of biomarker tests to guide decisions about adjuvant chemotherapy in breast cancer patients (see pdf below).